OncoMatch/Clinical Trials/NCT04301843
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Is NCT04301843 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Eflornithine for neuroblastoma.
Treatment: Eflornithine — Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroblastoma
Prior therapy
Must have received: aggressive multi-drug chemotherapy — upfront
must have completed upfront therapy with at least 4 cycles of aggressive multi-drug chemotherapy
Cannot have received: DFMO
Exception: DFMO at a dose ≤ 1000mg/m2 BID and not in combination with etoposide
Subjects that received DFMO at a dose higher than 1000mg/m2 BID prior to this study are not eligible. Subjects that received a dose of DFMO in combination with etoposide are not eligible.
Lab requirements
Blood counts
total absolute neutrophil count anc ≥750/μl
Kidney function
estimated glomerular filtration rate (egfr) as calculated from the bedside schwartz equation (in units of ml/min/1.73 m2) or via radioisotope gfr of ≥ 70.
Liver function
ast and alt <5x upper limit of normal (normal=45), bilirubin <1.5x upper limit normal (normal=1.0). normal pt, ptt, fibrinogen.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama/Children's of Alabama · Birmingham, Alabama
- Arkansas Children's Hospital · Little Rock, Arkansas
- UCSF Benioff Children's Hospital Oakland · Oakland, California
- Rady Children's Hospital · San Diego, California
- Connecticut Children's Hospital · Hartford, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify